Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years old or greater~2. Patients diagnosed with cystic fibrosis (CF), genotype homozygous Phe508del~3. Subject has been started on lumacaftor-ivacaftor for clinical reasons, with no contraindication for starting the drug\* \* Contraindications for taking drug include abnormal liver enzyme tests, renal dysfunction, pregnancy or nursing mothers~Exclusion Criteria~1. Does not have a HgbA1c within 1 year prior to starting medication.~2. Has not been on the combination therapy for at least 2 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lumacaftor-ivacaftor (Type: EXPERIMENTAL): Subjects will be monitored for glycemic changes before and after starting lumacaftor-ivacaftor.

Based on this trial design, predict the completion outcome and termination type (if applicable).